# US 2021/0171554 A1 · Benzothiophene estrogen receptor modulators to treat medical disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171554 A1
- Document ID: US20210171554A1
- Status: Published application
- Kind: A1
- Application number: 17/176,962
- Filed: 2021-02-16
- Published: 2021-06-10
- Earliest claimed: 2018-08-16
- Assignees: G1 Therapeutics, Inc.
- Applicants: G1 Therapeutics, Inc.
- Inventors: Jay Copeland Strum
- Web page: https://patentgrep.com/patent/US20210171554A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- A61K 31/381: having five-membered rings
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/67: having sulfur as a ring hetero atom
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- C07D 333/64: Oxygen atoms
- C07D 333/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07F 9/655354: {condensed with carbocyclic rings or carbocyclic ring systems}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt, N-oxide, isotopic derivative, or prodrug thereof or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder. The invention also includes a combination thereof with another active agent such as a CDK inhibitor, including a CDK4/6 inhibitor, to treat a disorder mediated by the estrogen receptor, as described in more detail herein.

## Claims

### Claim 1

A compound selected from:
or a pharmaceutically acceptable salt thereof;
wherein
A is:
m is 1, 2, or 3;
n is 0, 1, 2, 3, or 4;
o is 0, 1, 2, 3, 4, or 5;
each Q is independently selected from the group consisting of —CHR5— and —CH2—;
Z1 is —O—, —C(R3)2—, or —S—;
Z2 is bond, —O—, —C(R3)2—, or —S—;
Z3 is —O— or —S—;
each R1 is independently selected from the group consisting of C1-C5alkyl, halogen, and C1-C3haloalkyl;
R2 is selected from the group consisting of hydroxyl, alkoxy, —NH—(CH2)n1—NR6R7, —NR6R7, 4-10 membered heterocycle, and 6-12 membered bicyclic heterocycle; wherein each heterocycle is optionally substituted with one, two, or three groups independently selected from R4;
n1 is 2, 3, 4, 5, or 6;
each R3 is independently selected from the group consisting of hydrogen, halogen, C1-C3alkyl, and C1-C3haloalkyl;
each R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C5alkyl, C1-C5haloalkyl, —COOH, —COOC1-C5alkyl, —CONH2, —CON(H)alkyl, and —CON(alkyl)2;
or two R4 substituents on the same carbon atom are optionally combined together with the carbon to which they are attached to form a
group, wherein n3 is 1, 2, 3, 4, or 5;
R6 and R7 are independently selected at each instance from the group consisting of hydrogen, C1-C12alkyl, and C2-C12haloalkyl;
R8 is selected from the group consisting of —C(O)R9, —OC(O)R9, —OP(O)(OR10)2, and —P(O)(OR10)2;
R9 is selected from the group consisting of hydrogen, C1-C5alkyl, —OR6, and —NR6R7;
each R10 is independently selected from the group consisting of hydrogen, C1-C5alkyl, and —C(O)C1-C5alkyl;
R11 is a 4-10 membered monocyclic heterocycle or a 6-12 membered bicyclic heterocycle;
wherein each heterocycle is optionally substituted with one, two, or three substituents independently selected from R4, and wherein the heterocycle is attached through a carbon atom;
R12 is a 5, 6, or 7-membered monocyclic or 6-12 membered bicyclic heterocycle; wherein each heterocycle is optionally substituted with one, two, or three substituents independently selected from R4, and wherein the heterocycle is attached through a carbon atom;
R13 is selected from the group consisting of hydroxyl, —C(O)R9, —OC(O)R9, —OP(O)(OR10)2, and —P(O)(OR10)2;
and R14, R15, and R16 are independently selected from the group consisting of hydrogen, C1-C5alkyl, halogen, and C1-C3haloalkyl; wherein at least one of R14, R15, and R16 is C1-C5alkyl, halogen, or C1-C3haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is of Formula:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, wherein A is

### Claim 4 (depends on 2)

The compound of claim 2, wherein R8 is —C(O)R9.

### Claim 5 (depends on 2)

The compound of claim 2, wherein R8 is —OC(O)R9 or —OP(O)(OR10)2.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is of Formula:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The compound of claim 6, wherein Y is

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is of Formula:
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The compound of claim 8, wherein Z is

### Claim 10 (depends on 8)

The compound of claim 8, wherein Z is

### Claim 11 (depends on 1)

The compound of claim 1, wherein R13 is hydroxyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein at least one of Z1, Z2, and Z3 is —O—.

### Claim 13 (depends on 1)

The compound of claim 1, wherein Z1, Z2, and Z3 are —O—.

### Claim 14 (depends on 1)

The compound of claim 1, wherein n is 0.

### Claim 15 (depends on 1)

The compound of claim 1 selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The compound of claim 15, wherein the compound is of structure:
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 15)

The compound of claim 15, wherein the compound is of structure:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 15)

The compound of claim 15, wherein the compound is of structure:
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method of treating an estrogen-related disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
